SCHEMBL3512696

SCHEMBL3512696

CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.71
ECE1 P42892 12/20 0.66
ALOX15 P16050 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7397641 1.00 ACE (0.71) ACEECE1ALOX15
SCHEMBL5481232 1.00 ACE (0.71) ACEECE1ALOX15
SCHEMBL8725890 1.00 ACE (0.71) ACEECE1ALOX15
SCHEMBL30051826 0.98 ACE (0.68) ACEECE1ALOX15
SCHEMBL29555460 0.96 ACE (0.66) ACEECE1ALOX15
SCHEMBL7404624 0.95 ACE (0.64) ACEECE1ALOX15
SCHEMBL30080510 0.95 ACE (0.64) ACEECE1ALOX15
SCHEMBL7404621 0.95 ACE (0.64) ACEECE1ALOX15
SCHEMBL30052487 0.94 ACE (0.63) ACEECE1
SCHEMBL30725664 0.94 ACE (0.70) ACEECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) 2026-03-12 US claimed
WO-2024235082-A1 USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS 海口桥水联合科技有限责任公司 2024-11-21 WO claimed
CN-115073550-B Dipeptide difunctional small molecule compound for activating enzyme catalytic reaction and application thereof 中国科学院青岛生物能源与过程研究所 2024-10-08 CN claimed
WO-1993011154-A1 INHIBITORS OF THE CONVERSION OF BIG ENDOTHELIN TO ENDOTHELIN BERLEX LABORATORIES, INC. (US) 1993-06-10 WO claimed
WO-2026107097-A1 SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF ENLAZA THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
US-20260137689-A1 INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS ALTO NEUROSCIENCE INC (US) 2026-05-21 US disclosed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
JP-2026510034-A バイオノミックス リミテッド 2026-03-27 JP disclosed
JP-2026510034-A バイオノミックス リミテッド 2026-03-27 JP disclosed
EP-4715061-A1 PREPARATION METHOD FOR L-AMINO ACID LIGASE AND USE THEREOF IN DIPEPTIDE SYNTHESIS Asymchem Life Science (Tianjin) Co., Ltd (CN) 2026-03-25 EP disclosed
EP-3604503-B1 ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM AJINOMOTO KK (JP) 2026-03-18 EP disclosed
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) 2026-03-12 US disclosed
WO-1996030393-A1 A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS WARNER-LAMBERT COMPANY (US) 1996-10-03 WO disclosed
EP-0663856-A1 APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS WARNER-LAMBERT COMPANY (US) 1995-07-26 EP disclosed
US-5324483-A Apparatus for multiple simultaneous synthesis WARNER-LAMBERT COMPANY (US) 1994-06-28 US disclosed
WO-1994008711-A1 APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS WARNER-LAMBERT COMPANY (US) 1994-04-28 WO disclosed
US-5036052-A Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition MORISHITA PHARMACEUTICAL CO., LTD. (JP) 1991-07-30 US disclosed
EP-0347890-A1 Amino acid nutrient compositions Roussel Morishita Co., Ltd. (JP) 1989-12-27 EP disclosed
EP-0127108-B1 PROCESS FOR PREPARING POLYPEPTIDES MERCK & CO. INC. (US) 1986-12-30 EP disclosed
US-4510083-A POTASSIUM, CESIUM OR RUBIDIUM CARBONATE BUFFER FOR COUPLING OF AMINO ACID N-CARBOXYANHYDRIDE WITH ANOTHER AMINO ACID OR PEPTIDE MERCK & CO., INC. (US) 1985-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP ACE 1190/4885ECE1 1629/4885ALOX15 4573/4885
US-20260137689-A1 INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS CHRNA5, CHRNA2, CHRNA4 ACE 3418/4885ECE1 4702/4885ALOX15 3294/4885
US-20260069651-A1 Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis VIP, ANPEP, RNPEP ACE 132/4885ECE1 363/4885ALOX15 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.